WO2026008004 - METHOD FOR TREATING ANTIPHOSPHOLIPID SYNDROME BY USING TACI-FC FUSION PROTEIN
National phase entry is expected:
Publication Number
WO/2026/008004
Publication Date
08.01.2026
International Application No.
PCT/CN2025/106768
International Filing Date
03.07.2025
Title **
[English]
METHOD FOR TREATING ANTIPHOSPHOLIPID SYNDROME BY USING TACI-FC FUSION PROTEIN
[French]
MÉTHODE DE TRAITEMENT DU SYNDROME DES ANTIPHOSPHOLIPIDES À L'AIDE D'UNE PROTÉINE DE FUSION TACI-FC
[Chinese]
用TACI-Fc融合蛋白治疗抗磷脂综合征的方法
Applicants **
REMEGEN CO., LTD.
Inventors
YANG, Chengde
SHI, Hui
LIU, Tingting
WANG, Wenxiang
FANG, Jianmin
Priority Data
202410895187.X
04.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1951 | |
| EPO | Filing, Examination, Granting | 15710 | |
| Japan | Filing, Examination, Granting | 2418 | |
| South Korea | Filing, Examination, Granting | 2637 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
28,056
Contact Us
Abstract[English]
The present invention relates to a drug for treating or alleviating antiphospholipid syndrome by using an effective amount of the drug targeting Blys and/or APRIL, a dosage regimen, an administration interval and an administration mode. The results show that the provided effective amount of the drug targeting Blys and/or APRIL exhibits good safety and excellent therapeutic effect during the treatment of alleviation of patients with antiphospholipid syndrome.[French]
La présente invention concerne un médicament pour le traitement ou le soulagement du syndrome des antiphospholipides à l'aide d'une quantité efficace du médicament ciblant Blys et/ou APRIL, d'un régime posologique, d'un intervalle d'administration et d'un mode d'administration. Les résultats montrent que la quantité efficace fournie du médicament ciblant Blys et/ou APRIL présente une bonne sécurité et un excellent effet thérapeutique pendant le traitement du soulagement de patients atteints du syndrome des antiphospholipides.[Chinese]
涉及利用有效量的靶向Blys和/或APRIL的药物治疗或缓解抗磷脂综合征的药物、剂量方案、给药间隔及施用方式。结果显示，提供的有效量的靶向Blys和/或APRIL的药物在治疗或缓解抗磷脂综合征患者过程中表现出良好的安全性和较佳的治疗效果。